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The  activation of resting B  lymphocytes and  their transition to  immunoglobulin 
(Ig)-secreting cells requires a  complex series of regulatory signals. It  has been  dem- 
onstrated in animal as well as human models of B cell activation that small resting B 
cells can be triggered in a polyclonal manner by modulation of the surface membrane 
Ig (sIg) of the B cell by anti-Ig or other Ig-cross-linking substances such as Staphylococcus 
aureus Cowan strain I  (SAC)  (i, 2). These activated cells then increase in size (3) and 
become  sensitive  to  proliferative signals  from  T  cell-derived B  cell  growth  factors 
(BCGF)  (4).  Subsequently,  other  T  cell-derived differentiation  factors  can  induce 
these activated and proliferating cells to terminally differentiate into Ig-secreting cells 
(2,  5-7).  Precise study of antigen-specific human  B  cells has been  hampered by the 
low precursor frequency of these cells in the peripheral blood B cell repertoire. In the 
present study, we have  immunized  normal subjects in  vivo with  a  specific antigen, 
pneumococcal  polysaccharide  (PPS),  and  have  noted  a  substantial  but  temporally 
restricted enrichment  in  the  peripheral blood  of activated PPS-specific B  cells  (8). 
This  has  allowed  us  to  identify,  purify,  and  characterize  these  activated  antigen- 
binding B  cells (ABC). 
Materials  and  Methods 
Immunizations.  Normal volunteers received 0.5 cc of the 14 valent PPS vaccine (Pneumovax; 
Lederle Laboratories, Pearl River, NY). 
Cell  Separations.  Buffy coats from  2  U  of blood were obtained  via standard blood bank 
procedures, and  the mononuclear cell population was separated via Ficoll-Hypaque density 
centrifugation. T cells were depleted by rosetting with 2-aminoethylisothiorouronium bromide- 
treated sheep erythrocytes (9). The B cell- and monocyte-enriched population was depleted of 
monocytes by passage over a G-10 column (10). The resultant B cells were separated into ABC 
and  non-ABC  by  rosetting with  ox  erythrocytes coated  with  PPS  vaccine  and  by  Ficoll- 
Hypaque density centrifugation. The ox erythrocytes were coated with PPS via the chromic 
chloride method. The Ficoll-Hypaque density centrifugation was repeated as needed to increase 
the purity to 60-70% rosette positive. Unless otherwise stated, all cells were obtained 7 or 8 d 
after immunization. 
Monoclonal Antibodies.  Mouse anti-human IgM, [gD, and IgG monoclonal antibodies were 
obtained from Bethesda Research Laboratories, Gaithersburg, MD and N. L. Cappel Labora- 
tories, Cochranville, PA. The 4F2 monoclonal antibody was prepared as previously described 
(II). 
Cell Size.  Cell volume was quantitated with a  Coulter channelizer (Coulter Electrics Inc., 
Hialeah, FL). 
Cell Surface Isotype.  1 X 106 B cells were incubated with a 1:50 dilution of various monoclonal 
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antibodies or a control supernatant for 30 min at 4°C and then washed twice with phosphate- 
buffered saline (PBS). Subsequently, PPS-coated ox erythrocytes were added and the number 
of  rosettes  was  scored  after  staining  with  50  /zg  of  acridine  orange  to  produce  nuclear 
fluorescence. 
4F2 Immunofluorescent Staining.  1 ×  108 cells were stained with 5/lg of purified 4F2 antibody, 
washed twice in PBS, and stained with a  1:50 dilution of an affinity-purified goat anti-mouse 
IgG. After two more washes, the cells were examined with the fluorescence-activated cell sorter 
(FACS) (B-D FACS Systems, Becton, Dickinson & Co., Sunnyvale, CA). 
Cell Culture and Assays.  25,000 ABC were cultured in 200/zl of RPMI  1640 containing 10% 
fetal calf serum  (Dutchland Laboratories, Inc., Denver, PA) supplemented with 20 #g/ml of 
gentamycin in round-bottomed microtiter plates (Linbro; Flow Laboratories, Inc., Rockville, 
MD).  Some cultures contained F(ab')2 fragment goat anti-human IgM antibody (50 #g/ml) 
purchased from N.  L. Cappel Laboratories, SAC, prepared and used as previously described 
(2),  25% BCGF derived from the human T-T hybridoma 2Bn as previously described (12), or 
a  combination of the above. Cultures were incubated in  100% humidity in 5% COz at 37°C. 
Cultures  were  pulsed  with  1  /~Ci of  [SH]thymidine  over  the  last  16  h  of a  3-d  culture. 
Incorporation of [ZH]thymidine was measured by standard liquid scintillation counting tech- 
niques after harvesting by a Titertek cell harvestor (Flow Laboratories, Inc.). Plaque-forming 
cell (PFC) and ABC assays were performed as previously described (8). 
Results and  Discussion 
Young adult normal  volunteers were immunized with the PPS  vaccine. 8  d  after 
immunization,  5-20%  of the  circulating purified  B  cell pool were  demonstrated  to 
specifically bind to the immunizing antigen by forming rosettes with PPS-coated ox 
erythrocytes,  and  0.5-2.0%  of B  cells spontaneously  secreted  anti-PPS  antibody  as 
detected  in  a  PPS-specific hemolysis-in-gel PFC  assay.  Before  immunization,  there 
were no detectable spontaneous anti-PPS PFC and <1 ABC per 1,000 B lymphocytes. 
In  addition,  PPS  in  vitro  could  not  stimulate  human  B  cells  to  proliferate  or 
differentiate either before or after in vivo immunization  (8).  Separation of the ABC 
from  B  cells that  did not bind antigen was performed by density gradient centrifu- 
gation of the  rosetted cells, and  cell volume  profiles were  determined  (Fig.  1).  The 
ABC were shown  to be large cells with an average cell volume of 320 #m a. Morpho- 
logically, these cells have large nuclei with dark blue cytoplasms, and  an occasional 
FIG.  1.  Volume distributions  of various lymphocyte  cell populations and morphology of ABC. 
Purified B cells were separated into rosette-positive and rosette-negative cells, and the cell volume 
profiles were determined.  The inset is a photomicrograph of a representative ABC. 1694  KEHRL AND FAUCI  BRIEF  DEFINITIVE REPORT 
cell was noted to be in mitosis  (Fig.  1, inset).  Thus, the size and morphology of these 
cells suggested that they had already been activated in vivo (13). 
Next,  the  sIg isotypes  of the  ABC  were  examined  by blocking the  formation  of 
rosettes  with  isotype-specific monoclonal antibodies  (14).  Two different  monoclonal 
antibodies  to IgD did not inhibit  the formation of ABC. Of the expected number of 
ABC, 36 +  15% were blocked by a  monoclonal antibody to IgM, and 84 +  5% were 
blocked by a monoclonal antibody to IgG. The addition of the IgM- and IgD-specific 
monoclonal  antibodies  resulted  in  inhibition  similar  to  that  found  with  the  IgM 
monoclonal antibody alone. Thus, the majority of ABC were sIgG positive and sIgD 
negative.  Furthermore,  IgG was the predominant  isotype spontaneously synthesized 
in vitro when these activated cells were placed in culture. Thus, the isotype expression 
of the ABC was also consistent with that of a  preactivated cell  (15). 
We have described a  mouse monoclonal antibody 4F2 which recognizes non-HLA, 
non-Ia cell surface determinants  on human monocytes, but not on resting human B 
or T  lymphocytes (11). However, the 4F2 antigen is expressed on lectin or alloactivated 
T  lymphocytes as well as all dividing human T  and B lymphoblastoid cell lines tested 
(11,  16).  Thus, it has served as an excellent marker of activated human lymphocytes 
and can be used to distinguish a  resting from an activated cell. Furthermore, 4F2 has 
been reported  to recognize different  molecular  forms on  human  T  and  B  lympho- 
blastoid cell lines  (17). 
The binding of 4F2 of ABC was demonstrated  by immunofluorescently staining a 
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FIG.  2.  Expression  of  an antigen recognized by the monoclonal antibody 4F2. In the upper portion 
of the figure, purified ABC were immunofluorescently stained with 4F2 and examined with the 
FACS. In the lower portion, B cells isolated from four individuals were similarly stained and then 
rosetted with PPS-coated ox erythrocytes and finally examined with a fluorescent microscope. KEHRL AND FAUCI  BRIEF  DEFINITIVE REPORT  1695 
purified B cell population from a recently immunized subject followed by rosetting of 
the cells with PPS-coated ox erythroeytes (Fig. 2). 4F2-positive cells were demonstrated 
virtually exclusively in the ABC fraction with only a rare 4F2-positive cell found in 
the non-ABC fraction. Confirmation of the binding of 4F2 to ABC is shown in the 
FACS pattern (Fig. 2). 
Given  the  fact  that  the  ABC  are  activated,  it  is  likely that  they  received  an 
activation signal in vivo by modulation of their sIg with PPS antigen. In our recently 
described in  vitro model of B  cell activation  (4),  resting human  B  cells could  be 
activated to proliferate in response to BCGF by prior stimulation with anti-/~ or SAC 
(presumably  by  inducing  the  expression  of BCGF  receptors).  In  contrast,  large 
activated cells could respond directly to BCGF, indicating that they already expressed 
receptors for the factor and could not be further activated by anti-/~  (4). 
In  the  present  study,  the  ABC  did  not  respond  to  signals  capable  of inducing 
proliferation of resting B cells, but they could respond directly to BCGF by increased 
proliferation. As shown in Fig. 3, when a monoclonal BCGF derived from a  human 
T-T hybridoma  (2Bll)  (12)  was  added  to cuhures of ABC, high  levels of tritiated 
thymidine incorporation were noted that were not further enhanced by the addition 
of anti-/~ or SAC. As also noted in Fig. 3, the PPS-specific ABC manifested a relatively 
high  background  proliferation.  This  likely represented  low  levels  of spontaneous 
proliferation of the ABC and was unrelated to the rosetting procedures required for 
isolation of the ABC (data not shown). Thus, the ABC, which are refractory to anti- 
/~ and SAC but responsive to BCGF alone, differ from resting B cells, which respond 
poorly if at all to BCGF alone and show a substantial synergistic proliferative response 
to anti-/~ plus BCGF. 
These findings in an antigen-specific system can be integrated into the model of 
human B cell activation, proliferation, and differentiation. In this model, the initial 
signal is delivered in vivo by the immunizing antigen. Antigen-specific B cell activation 
occurs and is accompanied by cell enlargement and expression of the 4F2 activation 
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Fxc. 3.  Response  to anti-/x, SAC, and BCGF. Induction of tritiated thymidine incorporation of 
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antigen  together with  receptors  for BCGF.  At  this  point,  the cell does not  become 
further  activated  upon  stimulation  with  anti-#  or  specific  antigen;  however,  it 
proliferates briskly to direct stimulation with BCGF. Further differentiation is mani- 
fested by continued proliferation and the synthesis and secretion of specific antibody. 
Summary 
Activated pneumococcal polysaccharide (PPS)-specific human B lymphocytes have 
been purified and examined in vitro. They are large cells that are refractory to further 
activation by antigen, anti-Ig, or Staphylococcus aureus Cowan strain I, but they respond 
directly by proliferation to B cell growth factors. In addition, they express the isotype 
pattern of activated cells and a  surface marker of activated lymphocytes called 4F2. 
Finally, they contain a subset of cells that spontaneously secrete PPS-specific antibody. 
Received  for publication 8 December 1982. 
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